Targeting Inflammation and Immune System in Acute Myocardial Infarction

Area of Science:

• Cardiovascular Science
• Inflammation Biology
• Pharmacology

Background:

• Atherosclerosis pathogenesis is increasingly linked to inflammation.
• Current acute coronary syndrome (ACS) management offers secondary prevention but lacks comprehensive inflammation-targeted therapies.
• The role of inflammation in atherothrombosis and coronary heart disease (CHD) requires further elucidation.

Discussion:

• The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated that canakinumab, an interleukin-1β inhibitor, significantly reduced high-sensitivity C-reactive protein (hsCRP) and cardiovascular events.
• Conversely, the Cardiovascular Inflammation Reduction Trial (CIRT) found no cardiovascular benefit with methotrexate, a non-specific anti-inflammatory drug, despite no reduction in hsCRP.
• These contrasting results raise questions about the efficacy of specific versus non-specific anti-inflammatory interventions in managing cardiovascular outcomes.

Key Insights:

• Targeting specific inflammatory pathways, like interleukin-1β with canakinumab, may effectively reduce cardiovascular risk in patients with established coronary heart disease.
• Non-specific anti-inflammatory treatments may not confer cardiovascular benefits, highlighting the need for precision in therapeutic targets.
• hsCRP levels, while reduced by canakinumab, may not be the sole indicator of therapeutic success; direct impact on clinical outcomes is crucial.

Outlook:

• Further research is needed to identify precise inflammatory targets for cardiovascular disease prevention and treatment.
• Investigating the mechanisms behind the differential effects of specific versus non-specific anti-inflammatories is essential.
• Developing targeted anti-inflammatory therapies holds potential for improving secondary prevention strategies in coronary heart disease.